Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review
The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aim of this paper was to perform a systematic review and, when feasible, a meta-analysis of randomized controlled trials (RCT) which used benzodiazepines (BZD) as a monotherapy versus placebo, antidepressant drugs (AD), or both. METHODS: Keyword searches were conducted for identifying RCT comparing BZD and AD, and/or placebo in the treatment of depression, using electronic databases from their inception up to April 2017. We selected reports of RCT in which BZD were compared to AD and/or placebo in the treatment of adult patients with a primary diagnosis of depressive disorder or anxious depression. When feasible, data were subjected to meta-analysis. RESULTS: A total of 38 studies met the criteria for inclusion and were then included in the systematic review. Only 1 study concerned a newer AD, fluvoxamine. For the meta-analysis, we submitted data on response rate from 22 RCT, considering BZD versus placebo (8 comparisons) and BZD versus tricyclic antidepressants (TCA) (20 comparisons). There was a lack of significant differences as to response rate between BZD and placebo, as well as between BZD and TCA. Analysis of individual studies disclosed that, in more than half of the studies comparing BZD to TCA and/or placebo, BZD were significantly more effective than placebo and as effective as TCA. CONCLUSIONS: BZD are a therapeutic option in anxious depression and there are no indications that AD are preferable. There is a pressing need for RCT of adequate methodological quality and follow-up comparing BZD to second-generation AD and placebo in anxious depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, BZD have been evaluated as monotherapy for depression with no observed difference from tricyclic antidepressants (TCA) in a meta-analysis of 20 trials from the 1970's to early 1990's.140”
In the citing paper
“It should also be remembered that benzodiazepines were found to be effective in anxious and mild depression.77”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [77]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Self-citationKessler, R. C., Sampson, N. A., Berglund, P., Gruber, M. J., Al-Hamzawi, A., Andrade, L., Bunting, B., Demyttenaere, K., Florescu, S., de Girolamo, G., et al. (2015) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796015000189 · Cited by 636
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Cited by
Als, T. D., Kurki, M. I., Grove, J., Voloudakis, G., Therrien, K., Tasanko, E., Nielsen, T. T., Naamanka, J., Veerapen, K., Levey, D. F., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02352-1 · Cited by 324
Clinical characterization of allostatic overload
Fava, G. A., McEwen, B. S., Guidi, J., Gostoli, S., Offidani, E., & Sonino, N. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.05.028 · Cited by 265
“, 2018) and in affective disorders (Benasi et al., 2018).”
Prévot, T., & Sibille, E. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0727-3 · Cited by 231
Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
Dubovsky, S. L., & Marshall, D. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524400 · Cited by 171
Allopregnanolone in postpartum depression: Role in pathophysiology and treatment
Meltzer-Brody, S., & Kanes, S. J. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100212 · Cited by 133
“As a monotherapy for MDD, few randomized controlled trials have examined benzodiazepines since the 1990s, and meta-analyses of these studies show no significant response rate versus placebo in depressive disorders (Benasi et al., 2018).”
Lüscher, B., & Möhler, H. (2019) · F1000Research · doi:10.12688/f1000research.18758.1 · Cited by 105
Cerne, R., LIPPA, A. S., Poe, M. M., Smith, J. L., Jin, X., Ping, X., Golani, L. K., Cook, J. M., & Witkin, J. M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108035 · Cited by 94
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77
Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience
Fava, G. A., & Belaise, C. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000492693 · Cited by 77
Role of Benzodiazepines in Anxiety Disorders
Balon, R., & Starčević, V. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9705-0_20 · Cited by 82
Mental Pain as a Transdiagnostic Patient-Reported Outcome Measure
Fava, G. A., Tomba, E., Brakemeier, E.-L., Carrozzino, D., Cosci, F., Eöry, A., Leonardi, T., Schamong, I., & Guidi, J. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000504024 · Cited by 70
When Anxiety and Depression Coexist: The Role of Differential Diagnosis Using Clinimetric Criteria
Cosci, F., & Fava, G. A. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517518 · Cited by 63
Can psychomotor disturbance predict ect outcome in depression?
van Diermen, L., Vanmarcke, S., Walther, S., Moens, H., Veltman, E. M., Fransén, E., Sabbe, B., van der Mast, R. C., Birkenhäger, T. K., & Schrijvers, D. L. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.07.009 · Cited by 66
The rise and fall and rise of benzodiazepines: a return of the stigmatized and repressed
Balon, R., Starčević, V., Silberman, E. K., Cosci, F., Dubovsky, S. L., Fava, G. A., Nardi, A. E., Rickels, K., Salzman, C., Shader, R. I., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0773 · Cited by 57
Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology
Lim, B., Sproule, B. A., Zahra, Z., Sunderji, N., Kennedy, S. H., & Rizvi, S. J. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000316 · Cited by 50
GABA System in Depression: Impact on Pathophysiology and Psychopharmacology
Vecchia, A. D., Arone, A., Piccinni, A., Mucci, F., & Marazziti, D. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211115124149 · Cited by 60
Benzodiazepines or related drugs and risk of pneumonia: A systematic review and meta‐analysis
Sun, G., Zhang, L., Zhang, L., Wu, Z., & Hu, D. (2019) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5048 · Cited by 55
Fee, C., Prevot, T. D., Misquitta, K., Knutson, D. E., Li, G., Mondal, P., Cook, J. M., Banasr, M., & Sibille, E. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab002 · Cited by 45
Keeping up with the clinical advances: depression
Ragguett, R.-M., Tamura, J. K., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852919001159 · Cited by 27
Zoroufchi, B. H., Doustmohammadi, H., Mokhtari, T., & Abdollahpour, A. (2020) · Revista Internacional de Andrología · doi:10.1016/j.androl.2019.08.003 · Cited by 31
Duan, Y., Wei, J., Geng, W., Jiang, J., Zhao, X., Li, T., Jiang, Y., Shi, L., Cao, J., Zhu, G., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.05.059 · Cited by 20
Chang, G., Hou, P., Yang, W., Wang, C., Fan, P.-S., Liao, H.-J., & Chen, T. (2021) · Pharmaceuticals · doi:10.3390/ph14030267 · Cited by 17
“In 1969, doxepin was indicated for the first time to treat major depressive and anxiety disorders in the United States, where it is still accounts for >2 million annual prescriptions [2].”
BackgroundJiang, T., Feng, M., Hutsell, A., & Lüscher, B. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02835-8 · Cited by 17
“…chemogenetic stimulation protocol, we reasoned that drastically increasing GABAergic dendritic inhibition would interfere with activity-dependent plasticity at dendrites needed to increase the activity of target cells, as evidenced by the lack of antidepressant ef fi cacy of benzodiazepines [63].”
Benzodiazepine and unhealthy alcohol use among adult outpatients.
Hirschtritt, M. E., Palzes, V. A., Kline‐Simon, A. H., Kroenke, K., Campbell, C. I., & Sterling, S. (2019) · PubMed · Cited by 23
Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach
Pallanti, S., Zohar, J., Kasper, S. F., Möller, H., & Hollander, E. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.11.042 · Cited by 15
Repple, J., Bayas, M., Möser, C., Kobayashi, N. F., & Reif, A. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.02.903 · Cited by 10
“…for a long time, partially explaining the short-term, fast-acting positive effects of benzodiazepines on some depressive symptoms (39); meta-analyses have shown that they have antidepressant effects both in combination with conventional antidepressants (40) and when given as monotherapy (41).”
Benzodiazepines Reduce Relapse and Recurrence Rates in Patients with Psychotic Depression
Shiwaku, H., Fujita, M., & Takahashi, H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061938 · Cited by 10
“Similarly, although clinicians occasionally use benzodiazepines alongside antidepressants to alleviate anxiety or persistent sleep disorders, there are no systematic data demonstrating the effectiveness of benzodiazepines in the maintenance of remission in depression [11].”
BackgroundWho's afraid of benzodiazepines?
Balon, R. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000525207 · Cited by 9
Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression
Macejova, A., Kovacova, V., Tonhajzerová, I., Višňovcová, Z., Ferencová, N., Mlyncekova, Z., Kukucka, T., & Ondrejka, I. (2024) · Pharmaceuticals · doi:10.3390/ph17121627 · Cited by 10
“On the contrary, a recent systematic review and meta-analysis of randomized controlled trials showed that benzodiazepines used as monotherapy could be more effective than placebo in the short-term treatment of depression [29].”
Malyshev, A. V., Sukhanova, I. A., Ushakova, V. M., Zorkina, Y., Abramova, O. V., Morozova, A. Y., Zubkov, E. A., Mitkin, N. A., Pavshintsev, V. V., Doronin, I. I., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15040462 · Cited by 10
“Even though BZD may elevate mood, they exert limited effects on the core symptoms of depression [49].”
BackgroundOh, T. K., Park, H. Y., Han, J., & Song, I. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14517 · Cited by 8
Brexanolone and postpartum depression: what does it have to do with GABA?
Naguy, A. (2019) · Archives of Women s Mental Health · doi:10.1007/s00737-019-00986-0 · Cited by 7
Malyshev, A. V., Sukhanova, I. A., Zlobin, A. S., Gedzun, V. R., Pavshintsev, V. V., Васильева, Е. В., Zalevsky, A. O., Doronin, I. I., Mitkin, N. A., Golovin, A. V., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.705590 · Cited by 9
The use of biofeedback intervention in the improvement of depression levels: a randomised trial
Maynart, W. H. D. C., de Albuquerque, M. C. D. S., Veríssimo, R. C. S. S., Sarmento, P. D. A., da Silva, J. J., Costa, C. D. S. G., Santos, J. D. D. S., Pontes, C. D. O., Barros, M. C. D. S., Belo, F. M. P., et al. (2021) · Acta Neuropsychiatrica · doi:10.1017/neu.2020.46 · Cited by 6
Carlo, V. D., Grancini, B. M., Vismara, M. E. M., Benatti, B., Arici, C., Cremaschi, L., Cirnigliaro, G., Degoni, L., Oldani, L., Palazzo, C., et al. (2019) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2695 · Cited by 8
“taken into account that, contrary to guidelines recommendations, a recent review found no significant differences in acute treatment response (up to 12 weeks) between BZDs and tricyclic antidepressants in patients with depressive disorders (Benasi et al., 2018).”
Jiang, J., Queneau, Y., & Popowycz, F. (2023) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202300144 · Cited by 6
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Benzodiazepines at the crossroads: navigating therapeutic promise and perils of misuse
Figg, J., Love, C., Sorathia, V., Engelbart, M. K., Turner, A., & Elton, A. (2026) · Annals of General Psychiatry · doi:10.1186/s12991-025-00627-0 · Cited by 5
“BZDs are employed for a wide range of clinical indications, including insomnia, depression (with or without anxiety), catatonia, functional gastrointestinal complaints, coronary heart disease, alcohol withdrawal, and agitation [43–46].”
Seltorexant for major depressive disorder
Valentino, K., Teopiz, K. M., Wong, S., Zhang, M. C., Le, G. H., Choi, H., Ballum, H., Dri, C. E., Cheung, W., & McIntyre, R. S. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2452514 · Cited by 7
“The concept of applying sleep targeting interventions in depressed patients is not entirely novel, with agents such as benzodiazepines and zolpidem applied in the past [95,96].”
A guide to what works for depression: An evidence-based review
Morgan, A. J., Reavley, N. J., Jorm, A. F., Bassilios, B., Hopwood, M., Allen, N. B., & Purcell, R. (2019) · Cited by 5
Fava, G. A., Cosci, F., Montiel, C. B., & Tomba, E. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000495967 · Cited by 4
Troppoli, T. A., & Thompson, S. M. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.10.036 · Cited by 7
Holzbach, R., Hunold, P., & Konert, F. (2021) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1510-8425 · Cited by 3
Chapoutot, M., Meloni, F., Peter‐Derex, L., Bastuji, H., Leslie, W., Schoendorff, B., Heinzer, R. C., Nicolas, A., Higgins, S., Bourgeois, A., et al. (2025) · Journal of Behavioral and Cognitive Therapy · doi:10.1016/j.jbct.2025.100533 · Cited by 6
Modern approaches to the pharmacotherapy of postpartum depression
Овчинников, А. В., & Иродионовна, В. Т. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-11-70-81 · Cited by 4
Depressive and Anxiety Disorders
Gitlin, R. S., & Mieczkowski, A. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-50695-7_33 · Cited by 3
Benzodiazepines: Pharmacology Up-to-Date and Practical Issues
Kang, U. G., Kim, S. H., Lee, N. Y., Lee, K. Y., Kim, Y. S., & Chung, I. W. (2023) · 신경정신의학 · doi:10.4306/jknpa.2023.62.1.1 · Cited by 2
Study of delusional depression: Drive, dynamics, therapy
Bürgy, M. (2018) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2018.08.003 · Cited by 3
Psychoactive plants and phytochemicals
Salem, M. A., Zayed, A., & Ezzat, S. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821556-2.00028-1 · Cited by 4
Hindbrain networks: Exploring the hidden anxiety circuits in rodents
Zhou, Y., Wang, G., Liang, X., & Xu, Z. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115281 · Cited by 4
Zhao, F.-Y., Xu, P., Kennedy, G. A., Jin, X., Wang, Y., Zhang, W., Yue, L.-P., Ho, J. Y. S., Fu, Q.-Q., & Conduit, R. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s499574 · Cited by 2
“30 Historically, benzodiazepines were still considered viable monotherapy options after modern antidepressants emerged.”
Padma, K., Sonawane, S. M., Nanaware, S. S., N, U. T., & Ransing, R. S. (2022) · Psychiatria Danubina · doi:10.24869/psyd.2022.514 · Cited by 2
“Therefore, Escitalopram and lorazepam were prescribed to treat these symptoms (Benasi et al. 2018).”
BackgroundUchimura, N., Nakatome, K., Miyata, K., & Uchiyama, M. (2019) · Sleep and Biological Rhythms · doi:10.1007/s41105-019-00230-3 · Cited by 3
Cao, P., Li, Y., Yang, L., Guo, L., Hua, J., Zhang, S., Li, C., Dang, B., Sun, Y., Liu, M., et al. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02909-w · Cited by 2
“The interventions can be classified as. i) Pharmacological therapy: such as benzodiazepines [24], fluoxetine [25], vortioxetine [26], and alpra-zolam [27]. ii) Psychotherapy (offers to individuals, couples, families, or group members [28].”
Bonnet, U., Scherbaum, N., Juckel, G., & Bschor, T. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2846-4275 · Cited by 1
Paraschakis, A., Efstathiou, V., Karageorgiou, V., Boyokas, I., & Michopoulos, I. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114260 · Cited by 1
Kennedy, K. P., Heldt, J. P., & Oslin, D. W. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002025 · Cited by 2
González, C. Á., Zaragozá, C., & Lopez-Munoz, F. J. (2020) · Revista de Investigación y Educación en Ciencias de la Salud (RIECS) · doi:10.37536/riecs.2020.5.2.214 · Cited by 5
“Sin embargo, no existen comparaciones con los antidepresivos más modernos [46].”
BackgroundPhytosedatives for Drug Discovery
Ezzat, S. M., Zayed, A., & Salem, M. A. (2020) · doi:10.1002/9781119650034.ch7 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Karl Rickels Centenarian: Celebration of a Clinician-Scientist
Balon, R. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000542265 · Cited by 1
Nagel, L., & Bschor, T. (2018) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-018-2684-9
The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives
Sanacora, G., Kitay, B. M., & Wilkinson, S. T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00035-4
Knyahnytska, Y., Abbaspour, Z., & Kendzerska, T. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_406-1 · Cited by 1
Industrial Accident Induced Coma: A Multi-Disciplinary Perspective Within the Industry 4.0 Paradigm
Rodríguez, I., & Ochoa, A. (2021) · Lecture notes in intelligent transportation and infrastructure · doi:10.1007/978-3-030-68655-0_3
Vaaler, A. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0563
Knyahnytska, Y., Abbaspour, Z., & Kendzerska, T. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_406
Köhler, S., & Schefft, C. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_7
Golovenko, M. Y. (2025) · INTERNATIONAL NEUROLOGICAL JOURNAL · doi:10.22141/2224-0713.21.1.2025.1156
Les manifestations cliniques du sevrage après arrêt des antidépresseurs
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00002-9
Prévention de la dépendance et de la symptomatologie du sevrage dus aux traitements antidépresseurs
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00012-1
Research Progress on Acupuncture for the Treatment of Depression-Related Insomnia
刘, 亚. (2025) · Traditional Chinese Medicine · doi:10.12677/tcm.2025.1410604
Lee, W.-T., Chen, M., Fang, Y.-W., Chang, W.-S., Hsiao, K.-Y., Shia, B., Liou, H., & Tsai, M.-H. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04656-5
“In clinical practice, BZDs may be preferred when comorbid anxiety or depression is present [22, 23], whereas Z-drugs are often favored for their rapid onset and shorter half-life.”
Fujisawa, D., Yoshikawa, E., Fujimori, M., 幸子, 荒., Kobayakawa, M., Kurata, A., Kayano, A., Ichikura, K., Igarashi, Y., Otani, H., et al. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf209 · Cited by 1
“Effectiveness of anxiolytics for anxiety and depression has been established outside cancer settings [10, 11].”
Jiang, J. (2024) · theses.fr (ABES) · doi:10.70675/a475cfd9z1b5fz46beza0e7zea11424d2363 · Cited by 1
Intermediate Steps in the Practice of Psychopharmacology: The Role of Clinical Judgment
Fava, G. A., Dubovsky, S. L., & Balon, R. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002206
Haußmann, R., & Borchers, R. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2946-3364
Metadata
- Authors
- Benasi, G., Guidi, J., Offidani, E., Balon, R., Rickels, K., & Fava, G. A.
- Affiliations
- University of Bologna (IT)
- Pennsylvania State University (US)
- Wayne State University (US)
- University of Pennsylvania (US)
- University at Buffalo, State University of New York (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 87
- Issue
- 2
- Pages
- 65-74
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2790662831
- Cited by
- 79
- References
- 66
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 14 · 2020: 13 · 2019: 14 · 2018: 3
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- benzodiazepines, depression, monotherapy, antidepressants, tricyclic antidepressants, anxious depression, placebo comparison, treatment response rate, fluvoxamine, second-generation antidepressants
- MeSH terms
- Antidepressive Agents, Tricyclic, Benzodiazepines, Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.